絞り込み

16555

広告

J-Startupをはじめとするベンチャー企業の入札機会を拡大します

経済産業省は、関係府省庁と連携して、政府調達に関する統一基準を改訂しました。これにより、あらゆる規模の政府調達に対してJ-Startup企業の入札が可能となりま...

  1. FB、副社長に英の元副首相 規制強化のE...
  2. 選手は1型糖尿病 日本の患者励まし参戦 ...
  3. 日欧の水星探査機、打ち上げ成功…25年に...
  4. いつになったら我々は地球工学しか方法はな...

ニュース一覧

The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction.

著者 Trevisan R
Diabetes Ther.2017 Oct 05 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (90view , 0users)

Full Text Sources

Diabetes is the leading cause of chronic kidney disease, and even in the absence of albuminuria, decreased renal function in type 2 diabetes mellitus (T2DM) patients increases the risk for major adverse cardiovascular events and death. The evidence derived from recent studies suggests that intensive glucose control not only reduces the risk for microalbuminuria and macroalbuminuria but may also decrease the rate of decline of glomerular filtration rate (GFR). Although insulin therapy is widely used in patients with T2DM and renal disease, metabolic control is particularly difficult to achieve and manage because of the limited therapeutic options and the frequent comorbidities seen in this population. Recent evidence suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors may offer a better choice for improving glycemic control in T2DM patients with low GFR. This review will focus on vildagliptin, a DPP-4 inhibitor with a large body of evidence in patients with moderate to severe renal failure and a good clinical profile in terms of efficacy and safety. In particular, vildagliptin, with appropriate dose adjustment, provides clinically important reductions in glycated hemoglobin, without increasing weight and the risk of hypoglycemia even in patients with severe chronic kidney disease.
PMID: 28983844 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード